NEWARK, DE |—The long-acting implantable GLP-1 obesity devices market is valued at USD 59.1 million in 2025 and is projected to reach USD 76.0 million in 2026. Expanding at a robust CAGR of 28.50%, the market is expected to surge to USD 932.9 million by 2036. This growth reflects a fundamental shift in obesity care delivery, as stakeholders prioritize long-term therapy...